IP Library Granted Patent US 9,827,205
Granted Patent B2
US 9,827,205 · App. 12/636,718 · Granted Nov 28, 2017

Dry powder fibrin sealant

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,827,205
App. No.
12/636,718
Granted
Nov 28, 2017
Kind
B2
Abstract

The invention provides a composition comprising a mixture of first microparticles that comprise fibrinogen and trehalose, and second microparticles that comprise thrombin and trehalose. The invention further provides methods for treating wounds by administering the novel microparticle composition.

Claims (32)

1. A dry powder fibrin sealant composition, comprising:

a mixture of first microparticles that comprise fibrinogen and trehalose, and

second microparticles that comprise thrombin and trehalose,

wherein trehalose is the only stabilizing sugar in the first microparticles and second microparticles, and

wherein the concentration of trehalose in the first microparticles is sufficient to preserve at least 70% of fibrinogen activity after exposure of the first microparticles to a 25 kGy dose of gamma irradiation delivered at a rate of 8 kGy/hour.

2. The composition of claim 1 , wherein fibrinogen activity is measured by ELISA.

3. The composition of claim 1 , wherein fibrinogen activity is measured by clot strength assay.

4. The composition of claim 1 , wherein fibrinogen activity is measured by ELISA and clot strength assay.

5. The composition of claim 1 , wherein the concentration of trehalose in the first microparticles and second microparticles is sufficient to preserve at least 70% of expected clot strength after exposure of the mixture of microparticles to a 25 kGy dose of gamma irradiation delivered at a rate of 8 kGy/hour.

6. The composition according to claim 1 or claim 5 , wherein said first microparticles contain 0.5 to 20% w/w fibrinogen.

7. The composition of claim 6 , wherein said second microparticles comprise 10 to 20,000 IU/g thrombin.

8. The composition of claim 7 , wherein said second microparticles comprise 25 to 1,000 IU/g thrombin.

9. The composition of claim 1 or 5 , wherein said microparticles are spray-dried microparticles.

10. The composition of claim 9 , wherein the composition has a residual moisture content no greater than 5% (w/w).

11. The composition of claim 10 , wherein the residual content is no great than 3% (w/w).

12. The composition of claim 1 or claim 5 , wherein said first and second microparticles are mixed in a weight ratio of 1:1.

13. A method of treating a wound, comprising administering to the wound an effective amount of the composition as defined in claim 1 .

14. The method, as claimed in claim 13 , further comprising the step of applying pressure immediately after said administering.

15. The dry powder fibrin sealant composition of claim 1 , wherein the composition is sterilizable.

16. A method for preparing a dry powder fibrin sealant composition comprising a mixture of first microparticles that comprise fibrinogen and trehalose and second microparticles that comprise thrombin and trehalose, wherein trehalose is the only stabilizing sugar in the first microparticles and second microparticles, the method comprising:

(i) spray-drying a first aqueous solution comprising fibrinogen and trehalose to produce said first microparticles, wherein said first aqueous solution does not include a second stabilizing sugar and the concentration of trehalose in the first microparticles is sufficient to preserve at least 70% of fibrinogen activity after exposure of the first microparticles to a 25 kGy dose of gamma irradiation delivered at a rate of 8 kGy/hour;

(ii) spray-drying a second aqueous solution comprising thrombin and trehalose to produce said second microparticles, wherein said second aqueous solution does not include a second stabilizing sugar; and

(iii) mixing the first and second microparticles.

17. The method of claim 16 , wherein the concentration of trehalose in each of the first and second microparticles is sufficient to preserve at least 70% of expected clot strength after exposure of the mixture of microparticles to a 25 kGy dose of gamma irradiation delivered at a rate of 8 kGy/hour.

18. The method of claim 16 or claim 17 , wherein said first microparticles contain 0.5 to 20% w/w fibrinogen.

19. The method of claim 16 or claim 17 , wherein said second microparticles comprise 10 to 20,000 IU/g thrombin.

20. The method of claim 19 , wherein said second microparticles comprise 25 to 1,000 IU/g thrombin.

21. The method of claim 16 or claim 17 , wherein each of the first and second aqueous solutions is spray-dried with an outlet temperature of at least about 80° C.

22. The method of claim 21 , wherein the dry powder fibrin sealant composition has a residual moisture content no greater than 5% (w/w).

23. The method of claim 22 , wherein each of the first and second aqueous solutions is spray-dried with an outlet temperature of at least about 83° C.

24. The method of claim 22 , wherein the residual moisture content is no greater than 3% (w/w).

25. The method of claim 16 or claim 17 , wherein step (iii) comprises mixing the first and second microparticles in a weight ratio of 1:1.

Assignments (5)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 043596, FRAME 0259 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065610/0324 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Aug 18, 2017
From: MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 043596/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2017
From: PROFIBRIX BV
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 043197/0243 →